:

Has Medicare Approved Donanemab? A Guide to Coverage for Alzheimer's Treatment

In July 2024, the FDA granted traditional approval to donanemab (brand name Kisunla) for the treatment of early symptomatic Alzheimer's disease. This critical development directly influences coverage for beneficiaries asking, 'Has Medicare approved donanemab?' The answer is a qualified yes, with specific conditions to ensure patient safety and collect real-world data.